Physician profile

Allison Bryant

Women's Health (Nurse Practitioner) · Newnan, GA

NPI 1336561596

$272.00

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$41.68

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $66.45 2021
Astrazeneca Pharmaceuticals LP $42.71 2021
Seagen INC. $31.94 2021
Globus Medical, INC. $24.07 2023 Excelsiusgps Robotic Navigation System
Pharmacyclics LLC, An Abbvie Company $20.71 2021
Eisai INC. $20.23 2021
Deciphera Pharmaceuticals INC. $18.39 2021
Puma Biotechnology, INC. $17.61 2023
Daiichi Sankyo INC. $15.72 2021
Merck Sharp & Dohme LLC $14.17 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Allison Bryant

$272.00

in general payments reported 2019-2025

Years
2021-2023
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/11021687/allison-bryant

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.